Abstract
Acute myeloid leukemia (AML) with t(8;16)(p11;q13) is a distinct clinical and morphological entity with poor prognosis, which is characterized by a high frequency of extramedullary involvement, most commonly leukemia cutis; association with therapy related AML; frequent coagulopathy and morphologic features overlapping acute promyelocytic leukemia(APL). Herein, we present a case of 47 year-old post-menopausal woman developing secondary AML with t(8;16)(p11;q13) after 1 year of completion of therapy for breast carcinoma. Blasts were granulated with few showing clefted nucleus resembling promyelocytes and immnuophenotyping showed high side scatter with MPO positivity and CD 34 and HLA-DR negativity. In view of promyelocyte like morphology and immunophenotyping of blasts, possibility of APL was considered but, reverse transcription polymerase chain reaction (RT-PCR) for PML-RARα fusion transcript came out to be negative. Conventional cytogenetics showed t(8;16)(p11;q13). So, we should keep possibility of t(8;16) (p11;q13) in therapy related acute myeloid leukemia in patient showing clinical and morphological features of acute promyelocytic leukemia.
This is a preview of subscription content, log in via an institution to check access.
References
Gervais C, Murati A, Helias C et al (2008) Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogénétique hématologique. Leukemia 22:1567–1575
Marchesi F, Annibali O, Cerchiara E, Tirindelli MC, Avvisati G (2011) Cytogenetic abnormalities in adult non-promyelocytic acute myeloid leukemia: a concise review. Crit Rev Oncol Hematol 80:331–346
Haferlach T, Kohlmann A, Klein HU et al (2009) AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features. Leukemia 23:934–943
Diab A, Zickl L, Abdel-Wahab O et al (2013) Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Leuk Res 37:32–36
Daifu T, Kato I, Kozuki K et al (2014) The clinical utility of genetic testing for t(8;16)(p11;p13) in congenital acute myeloid leukemia. J Pediatr Hematol Oncol 36(5):e325–e327
Coenen EA, Zwaan CM, Reinhardt D et al (2013) Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group. Blood 122(15):2704–2713
Bernasconi P, Orlandi E, Cavigliano P et al (2000) Translocation (8;16) in a patient with acute myelomonocytic leukemia, occurring after treatment with fludarabine for a low-grade non-Hodgkin’s lymphoma. Haematologica 85(10):1087–1091
Rozman M, Camós M, Colomer D et al (2004) Type I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation. Genes Chromosomes Cancer 40(2):140–145
Informed Consent
Informed consent was obtained from the patient.
Conflict of Interest
All the authors declared that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chharchhodawala, T., Gajendra, S., Tiwari, P. et al. Therapy Related Acute Myeloid Leukemia with t(8;16) Mimicking Acute Promyelocytic Leukemia. Indian J Hematol Blood Transfus 32 (Suppl 1), 20–22 (2016). https://doi.org/10.1007/s12288-015-0527-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-015-0527-0